17,261 trials
Episodic Migraine Headache
Primary: Mean Change From Baseline in the Monthly Migraine Days During the 28-day Post Treatment Period Ending With Week 12 — -3.46; -6.27; -6.09 Days — p=< .0001
Graves' Ophthalmopathy
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment…
Chronic Rhinosinusitis
Primary: Change From Baseline in Nasal Polyp Score (NPS) to Week 16 — -0.87; -0.89; -0.49 score on a scale — p=0.2364
Euglycemia · Hypoglycemia · Hyperglycemia
Primary: The Primary Objective is to Determine the Ability of Intravenous Exenatide to: Maintain Intraoperative Euglycemia in Subjects With Initial Blood Glucose < 126 mg/dL in…
Retinitis Pigmentosa
Primary: Best Corrected Visual Acuity (BCVA) — 3.9; 1.3; 2.6 Letters correct — p=0.582
Multiple Myeloma
Primary: Overall Response Rate (PR or Better) of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory MM Refractory to a Previous…
Multiple Myeloma
Primary: Percentage of Participants With Progression-Free Survival — 65.3; 72.7; 55.3; 59.1 percentage of participants — p=1.0
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC v7
Primary: Objective Response Rate — 7; 0 percentage of participants
Severe Acute Respiratory Syndrome · Respiratory Failure · Acute Respiratory Distress Syndrome
Primary: PaO2/FiO2 Change (Increase) From Pre-to-post Intervention — 16.9; 29.8 percent change
Lymphangioleiomyomatosis (LAM)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 11 Participants
Ovarian Neoplasms
Primary: Progression Free Survival (PFS) Rate — 62 Percentage of participants
Portal Hypertension · Liver Cirrhosis
Primary: Safety (Incidence and Severity of Adverse Events) — 23; 2 Number of adverse events
Breast Cancer
Primary: Number of Participants of Clinically Relevant Toxicities (CRT) — 36; 13; 42; 26 Participants
Constipation
Primary: Bowel Movement (BM) Within 3 Days of Surgery — 29; 32 Participants — p=0.41
HIV Infections
Primary: Cmax of Rosuvastatin — 6.70; 16.32 ng/mL